Novo Nordisk is getting a boost from its new Wegovy weight-loss pill. | REUTERS
REUTERS
Aug 3, 2026
London – Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now, they may have reason for hope.
Despite Novo having lost ground in injectable GLP-1s in recent years, the Danish obesity drugmaker is getting a boost from its new Wegovy weight-loss pill that is holding onto its lead against Lilly’s more recently launched Foundayo.
The pair are battling for dominance in the obesity drug market, which analysts expect to be worth more than $100 billion by the end of the decade in the United States alone. Novo’s shares have climbed some 35% from a March low, with the company looking to go on the offensive — including with a divisive court case against Lilly over what it calls misleading marketing in the vital U.S. market.
In a time of both misinformation and too much information,
quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
